We track 9 organisations in this sector across 5+ countries.
9 entries.
Managing Partner and co-founder of Fountain Healthcare Partners. A pharmacist by training and former Elan executive, he invests across biopharmaceuticals and medical devices and has helped guide the firm's three funds and more than €425M under management.
Amber Therapeutics is an Oxford-based bioelectronics medtech company developing next-generation implantable neuromodulation devices for pelvic and nervous system disorders such as overactive bladder. Spun out from the University of Oxford, the company combines advanced microelectronics with closed-loop stimulation algorithms that adapt treatment in real time based on patient physiology. Amber has raised funding from deep-tech and life-science investors to advance its platform through clinical development. The company represents a growing wave of UK-based bioelectronic medicine startups tackling chronic conditions with precision device therapies.
Apex Ventures is a Vienna-based seed-stage venture capital firm launched in 2017 by Andreas Schwarzenbrunner, Wolfgang Berner, and Ulrich Gall, focused on deep tech, AI, medical devices, and digital health. The firm manages over EUR 50M and invests EUR 250K-1.5M in science-driven teams with defensible intellectual property, often emerging from leading European research institutions. Apex has backed companies including Prewave, Ribbonfish, and contextflow, and provides hands-on support in technology commercialization and clinical market access.
Fountain Healthcare Partners is Ireland's largest dedicated life-sciences venture firm, founded in 2008 as a spin-out from Elan Corporation's investment group. Headquartered in Dublin with an office in New York, it was established by Manus Rogan, Aidan King, Ena Prosser and Justin Lynch, and manages more than €425M across four funds. The firm invests at seed and early stage across specialty pharma, biopharmaceuticals, medical devices and diagnostics — primarily in Europe with selective US positions — typically leading or co-leading syndicates with €0.5–7M initial cheques and active follow-on. Fund III closed at €125M in 2020 with anchor commitments from the European Investment Fund, the Ireland Strategic Investment Fund, AIB and Japan's Kyowa Kirin, and Fund IV is now active. The portfolio has produced landmark exits including Inflazome (acquired by Roche for €380M upfront, 2020), KaNDy Therapeutics (Bayer, $425M upfront, 2020), Syndesi Therapeutics (AbbVie, 2022), Calypso Biotech (Novartis, 2024) and Vivasure Medical (Haemonetics, 2026). Active holdings include the Irish medtechs Neuromod Devices and Neurent Medical, Germany's Exciva and Belgium's Dualyx.
Partner and co-founder of Fountain Healthcare Partners, where he leads medical-device investments. He brings operating and finance experience to the firm's medtech portfolio, supporting companies through clinical development, regulatory milestones and exits.
Kerecis is an Icelandic biotech and medical technology company known for developing wound-healing products derived from fish skin. Its work is notable because it turns a locally abundant natural material into a clinically relevant regenerative scaffold used in difficult wound-care cases, including burns, trauma, and chronic ulcers. The biological rationale and manufacturing approach set it apart from software-led health companies: this is a deep life-science and materials business built around research, regulatory rigor, and medical adoption. In the European ecosystem, Kerecis is a useful example of how world-class biotech can emerge from a small geography when the product is grounded in differentiated science and clear clinical utility. It expands the directory's health coverage into advanced materials and tissue regeneration, complementing digital health and wearable platforms without overlapping with them. For the broader startup map, Kerecis shows that high-impact European innovation is not limited to apps or infrastructure, but also includes biologically sophisticated products with global medical significance.
Warsaw Stock Exchange–listed remote cardiac diagnostics company. Its PocketECG platform combines a mobile ECG device with AI-assisted arrhythmia detection and a 24/7 diagnostic service used by clinics and providers in the US, Europe, and Asia. An early Movens Capital portfolio company (IPO exit).
Seroba Life Sciences is a Dublin-based healthcare venture capital firm founded in 2002, investing in biotech, medical devices, and diagnostics across Europe with a focus on companies emerging from strong clinical and scientific foundations. The firm manages over EUR 300M and typically invests EUR 2-10M at Series A and B, taking board seats and providing strategic guidance on regulatory strategy and commercialization. Seroba has backed companies including Mainstay Medical, Aerogen, and Fire1, leveraging Ireland's deep life sciences talent pool and its proximity to major pharma and medtech multinationals headquartered in the country.
Connected smart stethoscope and AI platform that records and analyses lung and heart sounds for home-based respiratory diagnostics, paediatrics, and remote triage. Combines a CE-marked medical device with cloud-based AI that flags abnormal sounds for physicians. Backed by Movens Capital.